# Geneseeq Technology

作为中国日益增长的国内多组学检测基础的一部分，参与该国的精准肿瘤基因组检测市场。

Source: https://cn.bioecon.ru/companies/geneseeq-technology/
Updated: 2026-07-20

- 国家: China

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 产能 | 高通量测序能力，迄今已处理超过310,000份临床样本 | https://na.geneseeq.com/our-technology-2/ |
| 认证 | 实验室和生产设施获CAP、CLIA、ISO 15189及ISO 13485认证 | https://biobase.whitefordresearch.com/companies/geneseeq-technology, https://na.geneseeq.com/geneseeq-receives-nmpa-approval-for-pantrkare-chinas-first-ngs-based-pan-solid-tumor-companion-diagnostic-kit-for-ntrk-gene-fusions/, https://na.geneseeq.com/wp-content/uploads/2025/10/ISO-13485-Certificate-%EF%BC%88UL%EF%BC%89.pdf |
| 监管批准 | 在中国获得多项 NMPA 批准的诊断试剂盒，包括 PanTRKare 和大型 NGS 检测面板，同时获得美国 FDA 许可及多项检测的 CE-IVD 标志 | https://na.geneseeq.com/geneseeq-receives-nmpa-approval-for-pantrkare-chinas-first-ngs-based-pan-solid-tumor-companion-diagnostic-kit-for-ntrk-gene-fusions/, https://www.prnewswire.com/news-releases/geneseeq-receives-nmpa-approval-for-pantrkare---chinas-first-ngs-based-pan-solid-tumor-companion-diagnostic-kit-for-ntrk-gene-fusions-302610192.html, https://www.vcbeathealth.com/article/59323 |
| 生产基地 | 核心实验室位于南京、上海、北京和广州；生产基地位于南京 | https://biobase.whitefordresearch.com/companies/geneseeq-technology, https://www.prnewswire.com/news-releases/geneseeq-and-astrazeneca-collaborate-to-build-guangzhou-bio-diagnostics-innovation-center-301276980.html |
| 员工人数 | 2025年年报报告339名员工;其他报告估计超过1,500名专业人员 (2025-12-31) [中等置信度] | https://qiye.qizhidao.com/company/b41e1887d23421f09f7b2f89eceeb303.html, https://www.investnj.org.cn/our-clients/client-profiles/geneseeq-technology-nanjing%ef%bf%bc/ |
| 营收 | 2025年全年人民币5.77亿元 (2025-12-31) | https://qiye.qizhidao.com/company/b41e1887d23421f09f7b2f89eceeb303.html, https://www.vcbeathealth.com/article/59323 |

独立来源: biobase.whitefordresearch.com, investnj.org.cn, na.geneseeq.com, prnewswire.com, qiye.qizhidao.com, vcbeathealth.com

## 技术

- [精准肿瘤学多组学诊断panel](https://cn.bioecon.ru/technology/multi-omics-diagnostic-panels-precision-oncology/)